ClinicalTrials.gg
TerminatedNCT05643170PENNANTUpdated Jun 12, 2024Results posted

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

A Phase 3 interventional study of Xanomeline and Trospium Chloride Capsules in Schizophrenia, sponsored by Karuna Therapeutics. Terminated at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by Karuna Therapeutics (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Why this study was terminated
Company's business decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
19th of 20
4 · median 178
Started
2022
with 1 other
Phase 3
14 of 20
4 open now
Registered
8th of 20
by date
Lead sponsor
5 of 20
Karuna Therapeutics

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 19th largest by enrollment, is one of 2 that started in 2022, is one of 14 in phase 3, and was the 8th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

This is a Phase 3b, 3-year, open-label, multi-center study in which patients with DSM-5 diagnosis of schizophrenia whose current medication(s) is not well tolerated and/or clinical symptoms are not well controlled will be switched to receive KarXT.

The primary objectives of the study are to assess the long-term safety and tolerability of KarXT and assess effectiveness, persistence, and durability of effect of KarXT through the Investigator Assessment Questionnaire (IAQ) and Clinical Global Impression - Severity of Illness (CGI-S) scale in patients with a diagnosis of schizophrenia.

The secondary objectives are to further assess the effectiveness using the Clinical Global Impression, Global Improvement (CGI-I), long-term safety and tolerability of KarXT, and evaluation of scores from multiple additional patient scales and assessments throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is aged 18 to 65 years, inclusive, at screening.
  2. Patient can provide .

    1. A signed informed consent form (ICF) must be provided before any study assessments are performed.
    2. Patient must be fluent (oral and written) in the language of the ICF to consent.
  3. Patient has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM 5 (American Psychiatric Association, 2013) criteria and has been in the continuous care of the clinician or practice for at least 6 months prior to entering the study.
  4. The patient is dissatisfied with the side effects or general tolerability of their current antipsychotic medication, and for this reason, desires to change medications. Or, the patient is dissatisfied with the overall effectiveness or benefit of their current antipsychotic medication, and for this reason, desires to change medications.
  5. The patient has not required psychiatric hospitalization, acute crisis intervention, or other increase in their level of care due to symptom exacerbation within 4 weeks of screening, and in the opinion of the investigator, is psychiatrically stable to be managed in an outpatient setting.
  6. The patient has a CGI-S score of ≤4 (moderately severe or less) at screening and baseline visits.
  7. For at least 30 days prior to screening, the patient must have been prescribed and have taken an oral antipsychotic medication daily at a dose and frequency consistent with the drug label.
  8. Patient has an identified, reliable caregiver/informant that is willing (by informed consent) and able to respond to the ZBI 22 caregiver burden scale at specified visits. If the patient has been the patient of the investigator for ≥6 months and, in the opinion of the investigator, the patient is self-sufficient, then a caregiver/informant may not be necessary.
  9. Patient resides in a stable living situation and is anticipated to remain in a stable living situation for the duration of the study, in the opinion of the investigator.
  10. If a woman of (WOCBP) or a man whose sexual partner(s) is a WOCBP, the patient must be willing and able to adhere to the guidelines as defined in Section 12.1 Appendix 1.

Exclusion criteria

Exclusion Criteria:

  1. Any primary disorder diagnosis other than schizophrenia within 12 months before screening. Exclusionary disorders include, but are not limited to, bipolar I or II disorder and schizoaffective disorder. Symptoms of mild mood dysphoria or anxiety are allowed, as long as these symptoms are not the primary focus of treatment.
  2. The patient has a history of or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, is likely to jeopardize the safety of the patient or the validity of the study results.
  3. Patient has a history of or is at high risk of urinary retention, gastric retention, or narrow angle glaucoma.
  4. Patient has a history of irritable bowel syndrome (with or without constipation) or constipation requiring treatment for more than 30 days within the last 6 months.
  5. Clinically significant abnormal finding on the physical examination, medical history, (ECG), or clinical laboratory results at screening.
  6. Patient is pregnant, lactating, or less than 3 months postpartum.
  7. Patient has tested positive for coronavirus disease 2019 (COVID-19) within 2 weeks of screening and/or baseline or patients who have prolonged symptoms of past infection, long COVID, that, in the opinion of the investigator, may interfere with the interpretation of safety during the study.
  8. Patient with extreme concerns relating to global pandemics, such as COVID-19, that precludes study participation.
  9. Patient is currently or recently (within 4 weeks of screening) involuntary hospitalization or incarceration.
  10. Patient participated in another clinical study in which they received an experimental or drug agent within 30 days prior to screening.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    KarXT

    Drug: Xanomeline and Trospium Chloride Capsules

Interventions

  • DrugXanomeline and Trospium Chloride Capsules

    Drug pages: Xanomeline · Trospium chloride

    KarXT 50 mg/20 mg BID KarXT 100mg/20 mg BID KarXT 125mg/30 mg BID

06

What researchers measure

Primary outcomes

  1. The Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation

    An Adverse Event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at Screening, worsens during the study, regardless of the suspected cause of the event.

    Time frame: From first dose to 28 days post last dose (up to approximately 113 days)

  2. Investigator Assessment Questionnaire (IAQ) Scores

    The Investigator's Assessment Questionnaire (IAQ) evaluates all health concerns associated with antipsychotic use in patients with schizophrenia or schizoaffective disorder. The IAQ total score is defined as the sum of 10 items (positive symptoms, negative symptoms, somnolence, weight gain, signs and symptoms of prolactin elevation, akathisia, EPS, cognition, energy, and mood) for a total max score of 50; each item is rated on a 5-point Likert scale (1 = Much better, 2 = Slightly better, 3 = About the same, 4 = Slightly worse, and 5 = Much worse) where higher score indicate increased health concerns.

    Time frame: At visit 1, 3, 5 (Baseline, week 4, 8), and early termination visit (study day 85)

  3. Clinical Global Impression - Severity of Illness (CGI-S) Scores

    The Clinical Global Impression - Severity (CGI-S) is a rating scale completed independently by a clinician that is used to measure illness and symptom severity in subjects with mental disorders. It is used to rate the severity of a subject's illness at the time of assessment. The modified CGI-S asks the clinician 1 question: "Considering your total clinical experience, how mentally ill is the subject at this time?" The clinician's answer is rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill subjects.

    Time frame: At visit 1, 2, 3, 5 (baseline, week 2, 4, 8)

Secondary outcomes

  1. The Number of Participants With Serious Treatment-Emergent Adverse Events (TESAEs)

    An SAE is any untoward medical occurrence that, in the view of either the investigator or Sponsor that: * Results in death. * Is life-threatening. * Results in inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity. * Is a congenital anomaly/birth defect. * Other important medical events

    Time frame: From first dose to 28 days post last dose (up to approximately 113 days)

  2. The Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)

    An Adverse Event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at Screening, worsens during the study, regardless of the suspected cause of the event. AESIs include orthostasis and liver function test (LFT) elevations (inclusive of drug induced liver injury \[DILI\]. Orthostasis will be defined as the patient being symptomatic with at least one of the following differences in orthostatic vitals between sitting position and standing after 2 minutes: * A decrease of systolic BP of 20 mmHg or more. * A decrease in diastolic BP of 10 mmHg or more. * An increase in HR of 30 bpm or more.

    Time frame: From first dose to 28 days post last dose (up to approximately 113 days)

  3. Clinical Global Impression - Improvement (CGI-I) Score

    The Clinical Global Impression - Improvement (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. Clinicians are asked: "Compared to the patient's condition at baseline, this patient's \[average\] condition has...?", and they rate as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse.

    Time frame: At visit 2, 3, 5 (Weeks 2, 4, 8)

  4. Medication Satisfaction Questionnaire (MSQ) Score

    The Medication Satisfaction Questionnaire (MSQ) is a single-item questionnaire that evaluates satisfaction with antipsychotic medication in schizophrenia patients rated on a 7-point scale (1 = Extremely dissatisfied, 2=Very dissatisfied, 3=Somewhat dissatisfied, 4=Neither satisfied nor dissatisfied, 5=Somewhat satisfied, 6 = Very satisfied, 7 = Extremely satisfied).

    Time frame: Visit 5 (Week 8)

07

Results

Posted Jun 12, 2024

Participant flow

Participant flow — Overall Study
MilestoneKarXT
Started4
Completed0
Not completed4
Withdrew: Withdrew from study treatment due to study termination3
Withdrew: Adverse event (ae) that lead to treatment discontinuation1

Outcome measures

PrimaryThe Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation

An Adverse Event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at Screening, worsens during the study, regardless of the suspected cause of the event.

Time frame:
From first dose to 28 days post last dose (up to approximately 113 days)
Reported as:
Count of participants · Participants
The Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation
ParticipantsKarXT
The Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Discontinuation1
PrimaryInvestigator Assessment Questionnaire (IAQ) Scores

The Investigator's Assessment Questionnaire (IAQ) evaluates all health concerns associated with antipsychotic use in patients with schizophrenia or schizoaffective disorder. The IAQ total score is defined as the sum of 10 items (positive symptoms, negative symptoms, somnolence, weight gain, signs and symptoms of prolactin elevation, akathisia, EPS, cognition, energy, and mood) for a total max score of 50; each item is rated on a 5-point Likert scale (1 = Much better, 2 = Slightly better, 3 = About the same, 4 = Slightly worse, and 5 = Much worse) where higher score indicate increased health concerns.

Time frame:
At visit 1, 3, 5 (Baseline, week 4, 8), and early termination visit (study day 85)
Reported as:
Mean · Score on a scale
Investigator Assessment Questionnaire (IAQ) Scores
Score on a scaleKarXT
Visit 1 (Baseline)30.00 ± 0.000
Visit 3 (Week 4)29.50 ± 4.950
Visit 5 (Week 8)32.50 ± 2.121
Early Termination Visit31.00 ± 1.414
PrimaryClinical Global Impression - Severity of Illness (CGI-S) Scores

The Clinical Global Impression - Severity (CGI-S) is a rating scale completed independently by a clinician that is used to measure illness and symptom severity in subjects with mental disorders. It is used to rate the severity of a subject's illness at the time of assessment. The modified CGI-S asks the clinician 1 question: "Considering your total clinical experience, how mentally ill is the subject at this time?" The clinician's answer is rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill subjects.

Time frame:
At visit 1, 2, 3, 5 (baseline, week 2, 4, 8)
Reported as:
Mean · Score on a scale
Clinical Global Impression - Severity of Illness (CGI-S) Scores
Score on a scaleKarXT
Visit 1 (Baseline)3.00 ± 0.000
Visit 2 (Week 2)3.00 ± 0.000
Visit 3 (Week 4)3.00 ± 0.000
Visit 5 (Week 8)3.50 ± 0.707
SecondaryThe Number of Participants With Serious Treatment-Emergent Adverse Events (TESAEs)

An SAE is any untoward medical occurrence that, in the view of either the investigator or Sponsor that: * Results in death. * Is life-threatening. * Results in inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity. * Is a congenital anomaly/birth defect. * Other important medical events

Time frame:
From first dose to 28 days post last dose (up to approximately 113 days)
Reported as:
Count of participants · Participants
The Number of Participants With Serious Treatment-Emergent Adverse Events (TESAEs)
ParticipantsKarXT
The Number of Participants With Serious Treatment-Emergent Adverse Events (TESAEs)1
SecondaryThe Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)

An Adverse Event (AE) is any symptom, physical sign, syndrome, or disease that either emerges during the study or, if present at Screening, worsens during the study, regardless of the suspected cause of the event. AESIs include orthostasis and liver function test (LFT) elevations (inclusive of drug induced liver injury \[DILI\]. Orthostasis will be defined as the patient being symptomatic with at least one of the following differences in orthostatic vitals between sitting position and standing after 2 minutes: * A decrease of systolic BP of 20 mmHg or more. * A decrease in diastolic BP of 10 mmHg or more. * An increase in HR of 30 bpm or more.

Time frame:
From first dose to 28 days post last dose (up to approximately 113 days)
Reported as:
Count of participants · Participants
The Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)
ParticipantsKarXT
The Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI)1
SecondaryClinical Global Impression - Improvement (CGI-I) Score

The Clinical Global Impression - Improvement (CGI-I) is a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. Clinicians are asked: "Compared to the patient's condition at baseline, this patient's \[average\] condition has...?", and they rate as: 1 = Very much improved; 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse.

Time frame:
At visit 2, 3, 5 (Weeks 2, 4, 8)
Reported as:
Mean · Score on a scale
Clinical Global Impression - Improvement (CGI-I) Score
Score on a scaleKarXT
Visit 2 (Week 2)3.50 ± 0.707
Visit 3 (Week 4)4.50 ± 0.707
Visit 5 (Week 8)4.50 ± 0.707
SecondaryMedication Satisfaction Questionnaire (MSQ) Score

The Medication Satisfaction Questionnaire (MSQ) is a single-item questionnaire that evaluates satisfaction with antipsychotic medication in schizophrenia patients rated on a 7-point scale (1 = Extremely dissatisfied, 2=Very dissatisfied, 3=Somewhat dissatisfied, 4=Neither satisfied nor dissatisfied, 5=Somewhat satisfied, 6 = Very satisfied, 7 = Extremely satisfied).

Time frame:
Visit 5 (Week 8)
Reported as:
Mean · Score on a scale
Medication Satisfaction Questionnaire (MSQ) Score
Score on a scaleKarXT
Medication Satisfaction Questionnaire (MSQ) Score6.00 ± 0.000

Adverse events

Collected over From first dose to 28 days post last dose (up to approximately 113 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
KarXT0/4 (0%)1/4 (25%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventKarXT
SchizophreniaPsychiatric disorders1/4
Most frequent other events
Showing 10 of 11
Most frequent other events
EventKarXT
DizzinessNervous system disorders1/4
AkathisiaNervous system disorders1/4
Orthostatic hypotensionVascular disorders1/4
Abnormal dreamsPsychiatric disorders1/4
AnxietyPsychiatric disorders1/4
Major depressionPsychiatric disorders1/4
Post procedural hypothyroidismInjury, poisoning and procedural complications1/4
NauseaGastrointestinal disorders1/4
AstheniaGeneral disorders1/4
Red blood cells urine positiveInvestigations1/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)KarXT
<=18 years0
Between 18 and 65 years3
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)KarXT
Female1
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)KarXT
Hispanic or Latino0
Not Hispanic or Latino4
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)KarXT
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White0
More than one race0
Unknown or Not Reported0
08

Study locations

5 sites
  • Advanced Discovery Research, LLC
    Atlanta, Georgia 30318, United States
  • Seven Counties Services, Inc.
    Louisville, Kentucky 40203, United States
  • Mid Ohio Behavioral Health
    Columbus, Ohio 43205, United States
  • OnSite Clinical Solutions, LLC
    Rock Hill, South Carolina 29732, United States
  • Integrated Clinical Research
    Saint George, Utah 84770, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Mar 2023, 3 months.

Results were first posted in Jun 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Dec 8, 2022
StartActual
Nov 8, 2022
Primary completionActual
Mar 1, 2023
CompletionActual
Mar 8, 2023
Results first posted
Jun 12, 2024
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05643170
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Nov 8, 2022
Primary completion
Mar 1, 2023
Completion
Mar 8, 2023
Results posted
Jun 12, 2024
Last update
Jun 12, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium chloride

Start the discussion